Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$67.99M

FY 2025 · Annual

Investing Cash Flow

-$7.93M

FY 2025 · Annual

Financing Cash Flow

$72.93M

FY 2025 · Annual

+46.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(282.02M)(92.56M)(51.93M)(69.41M)(5.35M)
Depreciation & Amortization36.13M37.7M41.85M37.5M1.27M
Deferred Income Tax00000
Stock-Based Compensation22.74M17.85M9.32M7.78M11.28M
Change in Working Capital(105.61M)(1.44M)(20.73M)(39.68M)16.47M
Accounts Receivables(24.03M)11.7M994K4.05M(14.14M)
Inventory(24.95M)19.79M(2.54M)(28.4M)(23.13M)
Accounts Payables(11.74M)1.5M(5.24M)(1.36M)3.08M
Other Working Capital(44.9M)(34.42M)(13.94M)(13.96M)50.66M
Other Non-Cash Items98.54M(34.7M)(1.9M)23.15M44.31M
Operating Cash Flow(252.97M)(73.15M)(23.38M)(40.66M)67.99M
Capital Expenditures(59K)(114K)0(33K)(291K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments40M0000
Other Investing Activities0000(7.93M)
Investing Cash Flow39.94M(114K)0(33K)(7.93M)
Debt Repayment44.78M(33M)(32M)7.9M4.63M
Common Stock Issued88.95M7.53M6.79M42.65M68.36M
Common Stock Repurchased000(1.27M)0
Dividends Paid00000
Other Financing Activities040.07M1K385K(63K)
Financing Cash Flow133.73M14.6M(25.21M)49.66M72.93M
Effect of Forex Changes00000
Net Change in Cash(79.29M)(58.67M)(48.59M)8.97M132.99M
Free Cash Flow(253.02M)(73.27M)(23.38M)(40.69M)67.99M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$5.3M
+ D&A$1.3M
+ Stock-Based Comp$11.3M
+ Deferred Tax$0
+ Working Capital$16.5M
+ Other Non-Cash$44.3M
= Operating Cash Flow$68.0M
- Capex-$291.0K
= Free Cash Flow$68.0M

Analysis

FY2025 free cash flow is $68.0M. FCF conversion is -1272.1% of net income. Operating cash flow was $68.0M, with capex of -$291.0K. The largest bridge item is Other Non-Cash at $44.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportOct 23, 2026
8-KCurrent reportOct 14, 2026
4Statement of changes in beneficial ownershipAug 10, 2026

Does AKBA generate free cash flow?

Akebia Therapeutics, Inc. (AKBA) generated $67.99M of free cash flow in fiscal 2025.

How much operating cash flow does AKBA produce?

Operating cash flow was $67.99M, before capital expenditures of $291,000.00.